Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)

University Hospital, Ghent14 enrolled

Overview

We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Vitiligo

Interventions

topical tacrolimus treatmentDRUG

4 applications (day 1,day 3, day 6 and day10)

topical pimecrolimus treatmentDRUG

4 applications (day 1, day 3, day 6 and day 10)

local mometasone furoate treatmentDRUG

4 applications (day 1, day 3, day 6 and day 10)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female, * Age 18-70 years, * Extensive vitiligo (\> 50% body surface area), * Patients asking for depigmenting therapy, * Not pregnant. Exclusion Criteria: * Children, * Non extensive vitiligo (\< 50% boy surface area), * Patients not asking for depigmenting therapies, * Pregnant.

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

percentage of skin pigmentation in the treated area

digital image analysis system for surface measurement

Time frame: after 1 day, 10 days, 30 days and 60 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.